219 related articles for article (PubMed ID: 22692287)
21. J1-31 protein expression in astrocytes and astrocytomas.
Shuangshoti S; Thorner PS; Ruangvejvorachai P; Saha B; Groshen S; Taylor CR; Malhotra S; Imam SA
Neuropathology; 2009 Oct; 29(5):521-7. PubMed ID: 19019178
[TBL] [Abstract][Full Text] [Related]
22. Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate?
Muragaki Y; Chernov M; Maruyama T; Ochiai T; Taira T; Kubo O; Nakamura R; Iseki H; Hori T; Takakura K
Minim Invasive Neurosurg; 2008 Oct; 51(5):275-9. PubMed ID: 18855292
[TBL] [Abstract][Full Text] [Related]
23. Pathological classification of brain tumors.
Pollo B
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):103-11. PubMed ID: 22617234
[TBL] [Abstract][Full Text] [Related]
24. [Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification].
Figarella-Branger D; Chappe C; Padovani L; Mercurio S; Colin C; Forest F; Bouvier C
Bull Cancer; 2013; 100(7-8):715-26. PubMed ID: 23831947
[TBL] [Abstract][Full Text] [Related]
25. Podoplanin: a marker for reactive gliosis in gliomas and brain injury.
Kolar K; Freitas-Andrade M; Bechberger JF; Krishnan H; Goldberg GS; Naus CC; Sin WC
J Neuropathol Exp Neurol; 2015 Jan; 74(1):64-74. PubMed ID: 25470350
[TBL] [Abstract][Full Text] [Related]
26. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
Michotte A; Neyns B; Chaskis C; Sadones J; In 't Veld P
Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
[TBL] [Abstract][Full Text] [Related]
27. Gliosis and glioma distinguished by acridine orange.
Sarnat HB; Curry B; Rewcastle NB; Trevenen CL
Can J Neurol Sci; 1987 Feb; 14(1):31-5. PubMed ID: 2434199
[TBL] [Abstract][Full Text] [Related]
28. Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing.
von Deimling A; Ono T; Shirahata M; Louis DN
Semin Neurol; 2018 Feb; 38(1):19-23. PubMed ID: 29548048
[TBL] [Abstract][Full Text] [Related]
29. Tissue array analysis for the differentiation of gliosis from gliomas.
Medina Villaamil V; Alvarez García A; Aparicio Gallego G; Díaz Prado S; Rivas López LA; Santamarina Caínzos I; Valladares Ayerbes M; Antón Aparicio LM
Mol Med Rep; 2011; 4(3):451-7. PubMed ID: 21468591
[TBL] [Abstract][Full Text] [Related]
30. Molecular markers in low-grade gliomas: predictive or prognostic?
Hartmann C; Hentschel B; Tatagiba M; Schramm J; Schnell O; Seidel C; Stein R; Reifenberger G; Pietsch T; von Deimling A; Loeffler M; Weller M;
Clin Cancer Res; 2011 Jul; 17(13):4588-99. PubMed ID: 21558404
[TBL] [Abstract][Full Text] [Related]
31. Microdissection-based genotyping assists discrimination of reactive gliosis from glioma.
Finkelstein SD; Mohan D; Hamilton RL; Sasatomi E; Swalsky PA; Lieberman FS
Am J Clin Pathol; 2004 May; 121(5):671-8. PubMed ID: 15151207
[TBL] [Abstract][Full Text] [Related]
32. EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis.
Burel-Vandenbos F; Benchetrit M; Miquel C; Fontaine D; Auvergne R; Lebrun-Frenay C; Cardot-Leccia N; Michiels JF; Paquis-Flucklinger V; Virolle T
J Neurooncol; 2011 Apr; 102(2):171-8. PubMed ID: 20652725
[TBL] [Abstract][Full Text] [Related]
33. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
Marko NF; Prayson RA; Barnett GH; Weil RJ
Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
[TBL] [Abstract][Full Text] [Related]
34. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
35. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of immunohistochemical expression analysis of metabolic-related molecules in differentiating between intracranial neoplastic and non-neoplastic lesions.
Makino K; Nakamura H; Hide T; Yano S; Kuroda J; Takahashi Y; Iyama K; Kuratsu J
Brain Tumor Pathol; 2013 Jul; 30(3):144-50. PubMed ID: 23064941
[TBL] [Abstract][Full Text] [Related]
37. Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles.
Rorive S; Maris C; Debeir O; Sandras F; Vidaud M; Bièche I; Salmon I; Decaestecker C
J Neuropathol Exp Neurol; 2006 Aug; 65(8):794-807. PubMed ID: 16896313
[TBL] [Abstract][Full Text] [Related]
38. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas.
Ducray F; Mokhtari K; Crinière E; Idbaih A; Marie Y; Dehais C; Paris S; Carpentier C; Dieme MJ; Adam C; Hoang-Xuan K; Duyckaerts C; Delattre JY; Sanson M
Eur J Cancer; 2011 Mar; 47(5):802-8. PubMed ID: 21194923
[TBL] [Abstract][Full Text] [Related]
40. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
